IBBiShares Biotechnology ETF

$9.1B

net assets, all share classes

0.44%

yearly cost, from the prospectus

252

positions on file

+50.6%

last 12 months

+14.7%

a year, over 3 years

+3.3%

a year, over 5 years

BlackRock Funds IIICash and short-term

12.0%

VRTX Vertex Pharmaceuticals

8.1%0.59% of VRTX

AMGN Amgen

7.8%0.36% of AMGN

GILD Gilead Sciences

6.8%0.39% of GILD

REGN Regeneron Pharmaceuticals

4.9%0.69% of REGN

ARGX argenx SE

3.8%0.62% of ARGX

ALNY Alnylam Pharmaceuticals, Inc.

3.1%0.70% of ALNY

NTRA Natera, Inc.

2.9%0.68% of NTRA

RVMD Revolution Medicines, Inc.

2.8%0.63% of RVMD

BIIB Biogen

2.5%0.71% of BIIB

1. HALOHalozyme Therapeutics, Inc.0.7% of the fund0.7% of the company
2. ADMAADMA Biologics, Inc.0.1% of the fund0.7% of the company
3. ZYMEZymeworks Inc.0.1% of the fund0.7% of the company
4. ZVRAZevra Therapeutics, Inc.0.1% of the fund0.7% of the company
5. TECHBio-Techne0.9% of the fund0.7% of the company
6. VCELVericel Corporation0.2% of the fund0.7% of the company

The closest is XBI (State Street SPDR S&P Biotech ETF): 40%of the two funds’ stock holdings are the same.

1. XBIState Street SPDR S&P Biotech ETF0.35% a year40% in common
2. VHTVanguard Health Care ETF0.09% a year17% in common
3. IWOiShares Russell 2000 Growth ETF0.24% a year14% in common
4. VBKVanguard Small-Cap Growth ETF0.05% a year12% in common
5. XLVState Street Health Care Select Sector SPDR ETF0.08% a year11% in common
6. IWMiShares Russell 2000 ETF0.19% a year9.6% in common

IBB costs 0.44% a year. Overlap counts only the stocks we can match to a listing; bonds, cash and unmatched foreign shares are left out. Every group of near-identical funds and what each costs.